Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-15
2009-11-03
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S274000, C514S066000
Reexamination Certificate
active
07612093
ABSTRACT:
Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.
REFERENCES:
patent: 3590028 (1971-06-01), Arcamone et al.
patent: 4012448 (1977-03-01), Smith et al.
patent: 4065562 (1977-12-01), Ohata et al.
patent: 4182767 (1980-01-01), Murai et al.
patent: 4260622 (1981-04-01), Junge et al.
patent: 4269857 (1981-05-01), Tokuda et al.
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4524060 (1985-06-01), Mughal et al.
patent: 4533668 (1985-08-01), Matsumura et al.
patent: 4611058 (1986-09-01), Koebemick
patent: 4612008 (1986-09-01), Wong et al.
patent: 4639436 (1987-01-01), Junge et al.
patent: 4765989 (1988-08-01), Wong et al.
patent: 4783337 (1988-11-01), Wong et al.
patent: 4806650 (1989-02-01), Schroder et al.
patent: 4849430 (1989-07-01), Fleet et al.
patent: 4880830 (1989-11-01), Rhodes
patent: 4940705 (1990-07-01), Böshagen et al.
patent: 4957926 (1990-09-01), Jacob et al.
patent: 5003072 (1991-03-01), Partis et al.
patent: 5011829 (1991-04-01), Hirsch et al.
patent: 5030638 (1991-07-01), Partis et al.
patent: 5039667 (1991-08-01), Tyrrell et al.
patent: 5041441 (1991-08-01), Radin et al.
patent: 5051407 (1991-09-01), Böshagen et al.
patent: 5068112 (1991-11-01), Samejima et al.
patent: 5132291 (1992-07-01), Gruber
patent: 5144037 (1992-09-01), Partis et al.
patent: 5151519 (1992-09-01), Behling et al.
patent: 5190765 (1993-03-01), Jao et al.
patent: 5221746 (1993-06-01), Partis et al.
patent: 5261724 (1993-11-01), Meiller et al.
patent: 5264356 (1993-11-01), Rohrschneider
patent: 5310745 (1994-05-01), Partis et al.
patent: 5331096 (1994-07-01), Koszyk et al.
patent: 5411970 (1995-05-01), Partis et al.
patent: 5444063 (1995-08-01), Schinazi et al.
patent: 5451679 (1995-09-01), Barta et al.
patent: 5472969 (1995-12-01), Platt et al.
patent: 5476859 (1995-12-01), Partis et al.
patent: 5491135 (1996-02-01), Blough
patent: 5525616 (1996-06-01), Platt et al.
patent: 5536732 (1996-07-01), Lesur et al.
patent: 5595981 (1997-01-01), Barta et al.
patent: 5612480 (1997-03-01), Barta et al.
patent: 5622972 (1997-04-01), Bryant et al.
patent: 5663342 (1997-09-01), Barta et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5750648 (1998-05-01), Chang et al.
patent: 5905068 (1999-05-01), Chen et al.
patent: 6037351 (2000-03-01), Block et al.
patent: 6093702 (2000-07-01), Malley et al.
patent: 6245749 (2001-06-01), Schinazi et al.
patent: 6515028 (2003-02-01), Mueller et al.
patent: 6689759 (2004-02-01), Jacob et al.
patent: 6720001 (2004-04-01), Chen et al.
patent: 6809083 (2004-10-01), Mueller et al.
patent: 2003/0100532 (2003-05-01), Jacob et al.
patent: 2004/0132161 (2004-07-01), Finkel et al.
patent: PI 9902585 (2000-09-01), None
patent: 4307883 (1993-09-01), None
patent: 0 286 418 (1988-05-01), None
patent: 0 324 328 (1989-07-01), None
patent: 0 350 012 (1990-01-01), None
patent: 0 367 748 (1990-05-01), None
patent: 0 401 194 (1990-12-01), None
patent: 0 449 026 (1991-10-01), None
patent: 0 477 160 (1992-03-01), None
patent: 0 494 850 (1992-07-01), None
patent: 0 566 556 (1993-10-01), None
patent: 0 691 327 (1996-01-01), None
patent: 0 729 747 (1996-09-01), None
patent: 2700267 (1994-07-01), None
patent: 2020278 (1979-11-01), None
patent: WO 87/03903 (1987-07-01), None
patent: WO 90/14091 (1990-11-01), None
patent: WO 91/03242 (1991-03-01), None
patent: WO 91/17145 (1991-11-01), None
patent: WO 93/18763 (1993-09-01), None
patent: WO 94/04546 (1994-03-01), None
patent: WO 95/06061 (1995-03-01), None
patent: WO 95/19172 (1995-07-01), None
patent: WO 95/22975 (1995-08-01), None
patent: WO 96/40110 (1996-12-01), None
patent: WO 97/00881 (1997-01-01), None
patent: WO 98/35685 (1998-08-01), None
patent: WO 99/29321 (1999-06-01), None
patent: WO 99/40916 (1999-08-01), None
patent: WO 2004/047198 (2000-08-01), None
Abe et al., “Improved Inhibitors of Glucosylceramide Synthase,” J. Biochem., 1992. pp. 191/196, vol. 111.
Abe et al., “Induction of Glycosylceramide Synthase by Synthaso Inhibitors and Ceramide,” Biochemica et Biophysica Acta, 1996, pp. 333/341, vol. 1299.
Abe et al., “Structural and Stereochemical Studies of Potent Inhibitors of Glucosytceramide Synthase and Tumor Cell Growth,” Journal of Lipid Research, 1995, pp. 611-621, vol. 36.
Acosta et al., “Agents for Treating Human Immunodeficiency Virus Infection,” Am. J. Hosp. Pharm., vol. 51, Sep. 15, 1994, pp. 2251-2287.
Ardalan et al., “Mechanism of Action of a New Antitumar Agent, Carbetimer,” Cancer Research, 1986, pp. 5473-5476, vol. 46.
Arends, “Recueil des Travaux Chimiques des Pays/Bas,” Journal of the Royal Netherlands Chemical Society, Feb. 1994, Recl. Tray. Chim. Pays/Bas 113, 63/114, contents page only.
Beketic/Oreskovic et al., “Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdri Gene Activation by the Cyclosporin PSC 833,” Journal of the National Cancer Institute, 1995, pp. 1593-1602, vol. 87, No. 21.
Block et al., “Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar N-butyldeoxynojirimycin,” Mar. 1994, Proc. Natl. Acad. Sci., vol. 91, pp. 2235-2239.
Block et al., “The Secretion of Human Hepatitis B Virus is Inhibited by the Imino sugar, N-butyl-deoxynojirimycin,” Antiviral Research, vol. 23, No. Suppl. 01, Jan. 1, 1994, p. 79, XP002067579.
Block et al., “The Secretion of Human Hepatitis B Virus is Inhibited by the lmino Sugar, N-butyl-deoxynojirimycin,” undated, Jefferson Cancer Institute, et al.. No. 81, one page.
Block et al., “Treatment of Chronic Hepadnavirus Infection in a Woodchuck Animal Model with an Inhibitor of Protein Folding and Trafficking,” May 1998, Nature Medicine, vol. 4, No. 5, pp. 610-614.
Blum et al., “Antiviral Therapy of Hepatitis B Virus Infection: Blocking Viral Gene Expression,” Elsevier Science, B.V., Advanced Drug Delivery Reviews, 1995, pp. 321-331, vol. 17.
Bolhuis et al., “Mechanisms of Multidrug Transporters,” 1997, FEMS Microbiology Reviews, vol. 21, pp. 55-84.
Bradley et al., “Mechanism of Multidrug Resistance,” 1988, Biochimica et Biophysica Acta, vol. 948, pp. 87-128.
Bradley et al., “P/glycoprotein, Multidrug Resistance and Tumor Progression,” 1994, Cancer and Metastasis Reviews, vol. 13. pp. 223-233.
Cabot et al., “Tamoxifen Retards Glycosphingolipid Metabolism in Human Cancer Cells,” FEBS Letters, 1996, pp. 129-131, vol. 394.
Carbohydrate Chemistry, “Chapter 20: Nucleosides,” undated, pp. 242-276.
Chabner et al., “Reversal of Multidrug Resistance,” Jan. 1991, Journal of Clinical Oncology, vol. 9. No. 1. pp. 4-6.
Coates et al., “Developments in Viral Hepatitis During 1994,” Exp. Opin. Ther. Patents, 1995, pp. 747-756, vol. 5, No. 8.
Dalton et al., “A Phase III Randomized Study of Oral Verapamil as a Chemosensitizer to Reverse Drug Resistance in Patients with Refractory Myeloma,” Cancer, 1995, pp. 815-820, vol. 75, No. 3.
Dicato et al., “Multidrug Resistance: Molecular and Clinical Aspects,” Cytokines, Cellular & Molecular Therapy, 1997, pp. 91-100, vol. 3, No. 2.
Dienstag et al., “A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection,” The New England Journal of Medicine, 1995. pp. 1657-1661, vol. 333, No. 25.
Doige et al., “The Effects of Lipids and Detergents on ATPase/Active P/Glycoprotein,” 1993, Blochimica et Biophysics Acta, vol. 1146, pp. 65-72.
Doong et al., “
Block Timothy M.
Dwek Raymond A.
Jacob Gary S.
Foley & Lardner LLP
United Therapeutics Corporation
Wang Shengjun
LandOfFree
Compositions of treating hepatitis virus infections with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of treating hepatitis virus infections with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of treating hepatitis virus infections with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062027